CA3067031A1 - Gastro-resistant controlled release oral dosage forms - Google Patents

Gastro-resistant controlled release oral dosage forms Download PDF

Info

Publication number
CA3067031A1
CA3067031A1 CA3067031A CA3067031A CA3067031A1 CA 3067031 A1 CA3067031 A1 CA 3067031A1 CA 3067031 A CA3067031 A CA 3067031A CA 3067031 A CA3067031 A CA 3067031A CA 3067031 A1 CA3067031 A1 CA 3067031A1
Authority
CA
Canada
Prior art keywords
dosage form
controlled release
gastro
compound
resistant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3067031A
Other languages
English (en)
French (fr)
Inventor
Emmanuelle Georgi
Jay SAOUD
Remy Luthringer
Sandra Werner
Nadine Noel
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62904624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3067031(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of CA3067031A1 publication Critical patent/CA3067031A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3067031A 2017-06-21 2018-06-21 Gastro-resistant controlled release oral dosage forms Pending CA3067031A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523204P 2017-06-21 2017-06-21
US62/523,204 2017-06-21
PCT/US2018/038853 WO2018237207A1 (en) 2017-06-21 2018-06-21 GESTRO-RESISTANT ORAL DOSAGE FORMS WITH CONTROLLED RELEASE

Publications (1)

Publication Number Publication Date
CA3067031A1 true CA3067031A1 (en) 2018-12-27

Family

ID=62904624

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3067031A Pending CA3067031A1 (en) 2017-06-21 2018-06-21 Gastro-resistant controlled release oral dosage forms

Country Status (16)

Country Link
US (3) US11464744B2 (https=)
EP (1) EP3641732A1 (https=)
JP (3) JP2020525436A (https=)
CN (1) CN111511353A (https=)
AU (2) AU2018290287B2 (https=)
BR (1) BR112019027398A2 (https=)
CA (1) CA3067031A1 (https=)
CL (1) CL2019003743A1 (https=)
CO (1) CO2019014496A2 (https=)
IL (3) IL319156A (https=)
MX (1) MX2023002994A (https=)
NZ (1) NZ760127A (https=)
PE (1) PE20200732A1 (https=)
UA (1) UA127349C2 (https=)
WO (1) WO2018237207A1 (https=)
ZA (1) ZA202409847B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3227273T3 (pl) 2014-12-02 2022-05-30 Minerva Neurosciences, Inc. Kompozycje zawierające 2-((1-(2-(4-fluorofenylo)-2-oksoetylo)piperydyn-4-ylo)metylo)izoindolin-1-on do leczenia schizofrenii
IL319156A (en) 2017-06-21 2025-04-01 Minerva Neurosciences Inc Controlled-release oral dosage forms are resistant to gastric acid.
EP3840835A1 (en) 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
IT201800011125A1 (it) * 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico
EP4479049B1 (en) 2022-02-14 2025-12-17 Minerva Neurosciences, Inc. Use of roluperidone in preventing relapse in schizophrenia patients
WO2025090588A1 (en) 2023-10-24 2025-05-01 Minerva Neurosciences, Inc. Roluperidone for the treatment of lysosomal storage disorders and their symptoms

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3888340T2 (de) 1988-01-21 1994-06-30 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
ZA908641B (en) 1989-10-27 1992-06-24 Du Pont (n-phthalimidoalkyl)piperidines
CA2134077C (en) 1992-04-23 2002-05-21 Thaddeus R. Nieduzak 4-imidomethyl-1-[2'phenyl-2'oxoethyl-]piperidines as serotonin 5ht2-antagonists, their preparation and use in therapy
US7166617B2 (en) 2000-02-29 2007-01-23 Mitsubishi Pharma Corporation Cyclic amide derivatives
ATE361060T1 (de) 2000-09-29 2007-05-15 Solvay Pharm Bv Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
ES2405404T3 (es) 2003-10-29 2013-05-31 Wyeth Llc Composiciones farmacéuticas de liberación sostenida que comprenden aplindore y sus derivados
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
TW200616608A (en) 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
PE20061490A1 (es) 2005-06-06 2007-02-09 Merck Sharp & Dohme Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
US20090088449A1 (en) 2006-02-07 2009-04-02 Mitsubishi Tanabe Pharma Corporation 4-acylaminopyridine derivative mediated neurogenesis
CA2569776A1 (en) 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
KR20080089279A (ko) 2007-03-30 2008-10-06 미쓰비시 타나베 파마 코퍼레이션 우울증의 예방 및/또는 치료제
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
EP2246331A1 (en) 2009-04-24 2010-11-03 Westfälische Wilhelms-Universität Münster NR2B-selective NMDA-receptor antagonists
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
AR081935A1 (es) 2010-06-16 2012-10-31 Teijin Pharma Ltd Tableta con nucleo recubierto de liberacion controlada
US8937900B2 (en) 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
TWI520949B (zh) 2010-07-20 2016-02-11 錫蘭尼克藥物有限公司 使用環醯胺衍生物治療σ受體介導之病症的方法
RS64819B1 (sr) 2010-07-20 2023-12-29 Minerva Neurosciences Inc Metode upotrebe derivata cikličnih amida za lečenje šizofrenije i njenih simptoma
US20120040008A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
EP2468264A1 (en) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
KR20140045925A (ko) 2011-03-17 2014-04-17 루핀 리미티드 선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물
CA2845228C (en) * 2011-08-16 2021-08-10 Baker Idi Heart & Diabetes Institute Holdings Limited Oral controlled-release formulation of 5-(pyridinyl)-2(1h)-pyridinone compounds
AU2014239883B2 (en) * 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
CN104586771B (zh) * 2013-10-30 2018-01-16 广州朗圣药业有限公司 一种盐酸坦洛新缓释微丸制剂
MA39987A (fr) * 2014-04-30 2017-03-08 Incyte Corp Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées
EP3144308B1 (en) 2014-05-16 2020-06-24 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
KR102425303B1 (ko) * 2014-08-13 2022-07-25 세다르스-신나이 메디칼 센터 항-메탄생성 조성물 및 그것의 용도
PL3227273T3 (pl) 2014-12-02 2022-05-30 Minerva Neurosciences, Inc. Kompozycje zawierające 2-((1-(2-(4-fluorofenylo)-2-oksoetylo)piperydyn-4-ylo)metylo)izoindolin-1-on do leczenia schizofrenii
WO2017066134A1 (en) * 2015-10-16 2017-04-20 Merck Sharp & Dohme Corp. Processes for preparing formulations for gastrointestinal-targeted therapies
TWI820001B (zh) 2016-05-25 2023-11-01 日商田邊三菱製藥股份有限公司 醫藥組成物的用於製造非思覺失調症病患之負性症狀治療劑的用途
IL319156A (en) 2017-06-21 2025-04-01 Minerva Neurosciences Inc Controlled-release oral dosage forms are resistant to gastric acid.
EP3840835A1 (en) 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
WO2020264486A1 (en) 2019-06-28 2020-12-30 Teva Czech Industries S.R.O Solid state forms of roluperidone and salts thereof
EP4479049B1 (en) 2022-02-14 2025-12-17 Minerva Neurosciences, Inc. Use of roluperidone in preventing relapse in schizophrenia patients

Also Published As

Publication number Publication date
US20250009665A1 (en) 2025-01-09
IL308650A (en) 2024-01-01
JP2020525436A (ja) 2020-08-27
IL308650B2 (en) 2025-08-01
US12048768B2 (en) 2024-07-30
IL271606A (en) 2020-02-27
RU2020102015A (ru) 2021-07-21
ZA202409847B (en) 2025-09-25
IL308650B1 (en) 2025-04-01
CL2019003743A1 (es) 2020-07-03
CO2019014496A2 (es) 2020-04-01
IL271606B2 (en) 2024-05-01
AU2018290287B2 (en) 2024-06-13
WO2018237207A1 (en) 2018-12-27
US20220401368A1 (en) 2022-12-22
NZ760127A (en) 2026-02-27
IL271606B1 (en) 2024-01-01
RU2020102015A3 (https=) 2021-10-04
BR112019027398A2 (pt) 2020-07-07
MX2023002994A (es) 2023-09-15
UA127349C2 (uk) 2023-07-26
JP2025134828A (ja) 2025-09-17
JP2023175778A (ja) 2023-12-12
IL319156A (en) 2025-04-01
PE20200732A1 (es) 2020-07-23
AU2018290287A1 (en) 2020-01-16
US20190038561A1 (en) 2019-02-07
CN111511353A (zh) 2020-08-07
EP3641732A1 (en) 2020-04-29
AU2024219717A1 (en) 2024-10-03
US11464744B2 (en) 2022-10-11

Similar Documents

Publication Publication Date Title
US12048768B2 (en) Gastro-resistant controlled release oral dosage forms
RU2616516C2 (ru) Фармацевтическая композиция, содержащая олмесартана медоксомил и розувастатин или его соль
ES2797493T3 (es) Formulaciones farmacéuticas de liberación controlada de nitazoxanida
JP6333855B2 (ja) ビグアナイドを含む遅延放出組成物
AU2015355226B2 (en) Compositions comprising 2-((1-(2(4-Fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
US20150157575A1 (en) Pharmaceutical Formulations Comprising Vilazodone
RU2414903C1 (ru) Фармацевтический состав пролонгированного действия на основе клозапина перорального введения
RU2812901C2 (ru) Кишечнорастворимые лекарственные формы для перорального применения с контролируемым высвобождением
US20070053975A1 (en) Ramipril formulation
JP2018518521A (ja) モサプリドとラベプラゾールの複合製剤
TWI841545B (zh) 耐胃性控制釋放經口劑型
US20250367137A1 (en) Phloroglucinol Formulations And Methods Of Use
WO2024180559A1 (en) A stable tablet-in-tablet composition for nausea vomiting in pregnancy
RU2536254C1 (ru) Таблетки-ретард с тримебутином
JP2026501945A (ja) ナトリウム－グルコース共輸送体－２阻害剤およびアンジオテンシンｉｉ受容体遮断剤を含む経口用薬学製剤
TW202313019A (zh) Ppar促效劑與固醇吸收抑制劑之醫藥組合及其用途
KR20250084183A (ko) 다발성 경화증에 대한 치료용 티로신 키나제 저해제
WO2021234430A1 (en) Modified release dosage form comprising vildagliptin and process for manufacturing the same
TW202329971A (zh) 抗纖維化組合物
HK40021394A (en) Compositions and methods for treating metabolic disorders
HK40012109B (zh) 包含双胍的延迟释放组合物
HK40012109A (en) Delayed-release composition comprising biguanide

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220915

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240823

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250128

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250524

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250524

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250613

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250613

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260106